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Abstract
Arginase-induced L-arginine deprivation is emerging as a key mechanism for the downregulation
of immune responses. We hypothesised that arginase activity increases with disease severity in
HIV-seropositive patients. Our results show that peripheral blood mononuclear cells (PBMCs)
from 23 HIV-seropositive patients with low CD4+ T cell counts (≤350 cells/μl) expressed
significantly more arginase compared with 21 patients with high CD4+ T cell counts. Furthermore,
we found a significant association between the two principal prognostic markers used to monitor
HIV disease (CD4+ T cell count and plasma viral load) and PBMC arginase activity in
antiretroviral therapy naïve patients but not in patients undergoing therapy.
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1 Introduction
HIV results in a chronic infection that progressively impairs the immune system. Although
depletion of CD4+ T cells explains much of the immunosuppression, the precise
mechanisms involved in the onset of immunopathology during HIV infection have not yet
been resolved.
The metabolism of L-arginine by arginase is emerging as a crucial mechanism for the
regulation of immune responses. L-arginine has two principal metabolic fates; either it can
be metabolised by nitric oxide synthase into nitric oxide or by arginase into ornithine and
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urea. Arginase has been shown to impair T cell responses by reducing the bioavailability of
L-arginine: high arginase activity expressed by myeloid cells results in reduced availability
of extracellular L-arginine in the microenvironment. In turn, this decrease in L-arginine
results in T cell hyporesponsiveness.
To test the hypothesis that arginase activity is increased in HIV-seropositive (HIV+) patients
and might contribute to immune dysfunction and disease progression we measured the levels
of arginase activity in peripheral blood mononuclear cells (PBMCs) isolated from the blood
of HIV+ patients.
2 Materials and methods
The duration of the study was from February 2008 to December 2009 and a cohort of 44
HIV+ patients was recruited from St Mary's Hospital, London UK. Inclusion criteria were
(i) HIV+ by standard laboratory tests and (ii) older than 18 years. From the patient's hospital
records it was determined whether the patient was receiving antiretroviral therapy (ART).
All subjects gave written, informed consent before participation.
Plasma HIV-I viral RNA was quantified (Bayer Quantiplex assay; Bayer Diagnostics, East
Walpole, MA, USA). The standard T lymphocyte markers, CD3, CD4 and CD8 were
determined by flow cytometry.
Twenty millilitres of anticoagulated peripheral blood was collected in EDTA tubes and
PBMCs were isolated by density gradient centrifugation on Histopaque®-1077 (Sigma
Chemical Co., St. Louis, MO, USA).
The enzymatic activity of arginase was measured by a colorimetric enzymatic assay as
previously described. Arginase activity is expressed as mU per ml of blood.
Data were evaluated for statistical differences using a two-tailed Mann-Whitney U test and
for correlation using Spearman's rank test with GraphPad PRISM version 5.0 (Prism, San
Diego, CA, USA).
3 Results
We subdivided our cohort of HIV+ patients into two groups based on their CD4+ T cell
count. Arginase activity in PBMCs isolated from 23 HIV+ patients with low CD4+ T cell
counts (≤350 cells/μl) was significantly higher than that in 21 HIV+ patients with high
CD4+ T cell counts (median ± SEM: 2.2 ± 0.3 vs. 1.4 ± 0.1 mU/ml blood, respectively,
P < 0.001; Figure 1A). Moreover, we found a statistically significant inverse correlation
between arginase activity and CD4+ T cell count (r = −0.59, P < 0.001). In addition, our
results show that high viral load correlates with high arginase activity (r = 0.43, P = 0.003).
To assess the impact of ART on arginase activity we stratified the cohort into two groups.
The 22 patients on ART had a median (range) CD4+ T cell count of 475 (90–870) and 21 of
them had an undetectable plasma viral load (<1.7 log10 copies/ml). The 22 patients not on
ART had a median (range) CD4+ T cell count of 250 (0–800) and a median (range) plasma
viral load of 5.1 (2.66-5.67) log10 copies/ml.
Interestingly, a highly significant inverse correlation was found between CD4+ T cell count
and PBMC arginase activity in untreated but not in treated patients (untreated: r = −0.676,
P < 0.001 vs. treated: r = −0.231, P = 0.301; Figures 1B and C). In addition, a positive
association between plasma viral load and PBMC arginase activity was found in untreated
patients (r = 0.47, P = 0.03). As 21 of the 22 patients receiving ART had viral loads below
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detection limits association between arginase activity and viral load in these patients could
not be calculated.
These results show that both low CD4+ T cell count and high viral load correlate with high
arginase activity in untreated but not treated HIV+ patients.
4 Discussion
Our study reveals that arginase activity is significantly higher in PBMCs from HIV+ patients
with a low CD4+ T cell count, compared with that in HIV+ patients with a high CD4+ T cell
count. Moreover, we found that in ART naïve patients there is a significant association
between high PBMC arginase activity and both of the principal markers of HIV disease
progression, namely low CD4+ T cell count and high plasma viral load. Therefore, we
propose that the higher arginase activity detected in PBMCs from advanced untreated HIV+
patients may result in lower levels of L-arginine, thereby causing dysregulation of T cell
responses. One potential consequence of L-arginine starvation is altered T cell proliferation
as it has been shown that sub-physiological levels of L-arginine lead to G0-G1 cell cycle
arrest. A better understanding of the events resulting in the upregulation of arginase and the
subsequent downregulation of T cell responsiveness will improve our understanding of the
complex mechanisms leading to progressive immune dysfunction in HIV/AIDS and may
provide new targets to improve the efficacy of therapy.
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Figure 1.
Arginase activity in peripheral blood mononuclear cells isolated from 44 HIV-seropositive
patients. (A) Arginase activity in 21 patients with CD4+ T cell count > 350 cells/μl and 23
patients with CD4+ T cell count ≤350 cells/μl; ***P < 0.001. (B) Arginase activity and
CD4+ T cell counts for 22 patients not on antiretroviral therapy (ART). (C) Arginase activity
and CD4+ T cell counts for 22 patients on ART.
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